What Are the Long‐Term Clinical and Functional Outcomes After Hemicortical Allograft Reconstruction for Primary Bone Tumors?
Journal of Surgical Oncology · 2025
DOI: 10.1002/jso.28147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2025. Verfasst von Marcos R Gonzalez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Orthopaedic Oncology Service, Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Bone Neoplasms, Bone Transplantation, Tibia, Plastic Surgery Procedures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Background
Hemicortical allograft reconstruction is associated with low short‐term complication rates and excellent functional outcomes. However, data on their long‐term complication profile and patient‐reported outcomes is scarce to non‐existent.
Methods
Patients with hemicortical resection and allograft reconstruction for primary bone tumors were included. The Henderson classification for biologic reconstruction was used to classify allograft failures. Functional outcomes at a minimum of 10 years postoperatively were assessed.
Results
Twenty‐four patients with femur hemicortical allograft and 20 with tibia allograft were included. Allograft failure and reoperation occurred in 39% and 52% of patients, respectively. The main causes of allograft failure were infection, soft‐tissue failure, and structural failure (9% each). Tibia allografts had a higher rate of failure due to infection ( p = 0.02) and nonunion ( p = 0.049) compared to femur allografts. There were no differences in allograft failure‐free survival based on bone (tibia vs. femur) and osteosynthesis type (plate vs. screw and plates). Median TESS‐LE and LEFS scores were 98.8% and 87.5% for tibia allografts, and 98.1% and 97.5% for femur allografts, respectively.
Conclusion
Long‐term allograft failure‐free survival was excellent, with infection and soft‐tissue failures as the main failure mechanisms. At last follow‐up, patients who still had the hemicortical allograft displayed excellent functional outcomes. Level of Evidence Level IV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Orthopaedic Oncology Service, Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Marcos R Gonzalez, Santiago A Lozano-Calderón
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Gonzalez, M. R., Okay, E., Werenski, J. O., Connolly, J. J., Pfeiffer, A., Newman, E. T., Raskin, K. A., & Lozano-Calderón, S. A. (2025). What Are the Long‐Term Clinical and Functional Outcomes After Hemicortical Allograft Reconstruction for Primary Bone Tumors?. Journal of Surgical Oncology. https://doi.org/10.1002/jso.28147
Vancouver
Gonzalez MR, Okay E, Werenski JO, Connolly JJ, Pfeiffer A, Newman ET, et al. What Are the Long‐Term Clinical and Functional Outcomes After Hemicortical Allograft Reconstruction for Primary Bone Tumors?. Journal of Surgical Oncology. 2025. doi:10.1002/jso.28147
BibTeX
@article{Gonzalez2025,
author = {Gonzalez, Marcos R and Okay, Erhan and Werenski, Joseph O and Connolly, Joseph J and Pfeiffer, Andrew and Newman, Erik T and Raskin, Kevin A and Lozano-Calderón, Santiago A},
title = {What Are the Long‐Term Clinical and Functional Outcomes After Hemicortical Allograft Reconstruction for Primary Bone Tumors?},
journal = {Journal of Surgical Oncology},
year = {2025},
doi = {10.1002/jso.28147}
}
EUVIMED